Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples

Virchows Archiv

Volumn 434, Issue 6, 1999, Pages 497-501

  Boix Ferrero, Javier ^a   Pellín, Antonio ^a   Blesa, Rafael ^a   Adrados, Manuel ^b   Llombart Bosch, Antonio ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Hepatocellular carcinoma; p53 mutation

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GENETICS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPAIN;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032972555     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280050374     Document Type: Article

References (34)

1. 1. Altmann HW (1994) Hepatic neoformations. Pathol Res Pract 190:513-557
2. 2. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik J, Laue DP (1990) Patterns of expression of the p53 tumour suppressor gene in human breast tissues and tumors in situ and in vitro. Int J Cancer 46:839-844
3. 3. Bourdon JC, D'Errico A, Paterlini P, Grigioni W, May A, Debuire B (1995) p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology 108:1176-1182
4. 4. Bressac B, Kew M, Wands J, Ozturk M (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350:429-431
5. 5. Buetow KH, Sheffield VC, Zhu M, Zhou TU, Shen FM, Hino O, Smith M, McMahon BJ, Lanier AF, London WT, Redeker AG, Govindarajan S (1992) Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. 89:9622-9626
6. 6. Challen C, Lunec J, Warren W, Collier J, Bassendine MF (1992) Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 16:1362-1363
7. 7. Cohen C, DeRose PB (1994) Immunohistochemical p53 in hepatocellular carcinoma and liver cell dysplasia. Mod Pathol 7:536-539
8. 8. Coursaget P, Depril N, Chabaud M, Nandi R, Mayelo V, LeCann P, Yvonet B (1993) High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br J Cancer 67:1395-1397
9. 9. Debuire B, Paterlini P, Pontisso P, Basso G, May E (1993) Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 8:2303-2306
10. 10. Foster PL, Eisenstadt E, Miller JH (1983) Base substitution mutations induced by metabolically activated aflatoxin B1. Prac Natl Acad Sci USA 80:2695-2698
11. 11. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP, Thorgeirsson SS (1994) Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res 54:281-285
12. 12. Greenblatt MS, Bennet WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
13. 13. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329:1318-1327
14. 14. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC (1996) Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucl Acid Res 24:141-146
15. 15. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428
16. 16. Hsu HC (1994) Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol 4:1341-1347
17. 17. Kang YK, Kim CJ, Kim WH, Kim HO, Kang GH, Kim YH (1998) p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch 432:27-32
18. 18. Kress S, Jahn UR, Buchmann A, Bannasch P, Schwarz M (1992) p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res 52:3220-3223
19. 19. Kubicka S, Trautwein C, Schrem H, Tillmann H, Mann M (1995) Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J Hepatol 23:412-419
20. 20. Mazars GR, Jeanteur P, Lynch HT, Lenoir G, Theillet C (1992) Nucleotide sequence polymorphism in a hotspot mutation region of the p53 gene. Oncogene 7:781-782
21. 21. Mise K, Tashiro S, Yogita S, Wada D, Harada M, Fukuda Y, Miyake H, Isikawa M, Izumi K, Sano N (1998) Assesment of the biological malignancy of hepatocellular carcinoma: relationship to clinicopathlogical factors and prognosis. Clin Cancer Res 4:1475-1482
22. 22. Moran E (1993) Interaction af adenoviral proteins with pRB and p53. FASEB J 7:880-885
23. 23. Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 52:6358-6364
24. 24. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860
25. 25. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879
26. 26. Pellín A, Boix-Ferrero J, Carpio D, López-Terrada D, Carda C, Navarro S, Peydró-Olaya A, Triche TJ, Llombart-Bosch A (1997) Molecular alterations of the RB1, TP53, and MDM2 genes in primary and xenografted human osteosarcomas. Diagn Mol Pathol 6:333-341
27. 27. Scorsone K, Zhou YZ, Butel JS, Stagle BL (1992) p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res 52:1635-1638
28. 28. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VMG, Cawley H, Welsh JA, Hansen C, Bergasa NV, Junes EA, DiBisceglie AM, Trivers GE, Sandoval CA, Calderon LE, Muñoz Espinosa LE (1996) An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17:1007-1012
29. 29. Spinardi L, Mazars R, Theillet C (1991) Protocols for an improved detection of point mutations by SSCP. Nucl Acid Res 19:4009
30. 30. Teramoto T, Satonaka K, Kitazawa S, Fujimori T, Hayashi K, Maeda M (1994) p53 gene abnormalities are closely related to hepatoviral infections and occur at a late stage of hepatocarcinogenesis. Cancer Res 54:231-235
31. 31. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, Jay G (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41-47
32. 32. Unsal H, Yakicier C, Marcais C, Kew M, Volkmann M, Zentgraf H, Isselbacher KJ, Ozturk M (1994) Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 91:822-826
33. 33. Volkmann M, Hofmann WJ, Müller M, Räth U, Otto G, Zentgraf H, Galle PR (1994) p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hotspot mutation. Oncogene 9:195-204
34. 34. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC (1994) Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 91:2230-2234